Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

UroGen Pharma (URGN) Short-term Investments: 2016-2025

Historic Short-term Investments for UroGen Pharma (URGN) over the last 7 years, with Sep 2025 value amounting to $37.0 million.

  • UroGen Pharma's Short-term Investments fell 70.32% to $37.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $37.0 million, marking a year-over-year decrease of 70.32%. This contributed to the annual value of $64.7 million for FY2024, which is 54.17% up from last year.
  • UroGen Pharma's Short-term Investments amounted to $37.0 million in Q3 2025, which was down 42.24% from $64.0 million recorded in Q2 2025.
  • In the past 5 years, UroGen Pharma's Short-term Investments registered a high of $124.7 million during Q3 2024, and its lowest value of $21.1 million during Q2 2024.
  • In the last 3 years, UroGen Pharma's Short-term Investments had a median value of $37.0 million in 2025 and averaged $51.1 million.
  • Per our database at Business Quant, UroGen Pharma's Short-term Investments spiked by 343.41% in 2024 and then slumped by 70.32% in 2025.
  • UroGen Pharma's Short-term Investments (Quarterly) stood at $44.8 million in 2021, then decreased by 0.50% to $44.6 million in 2022, then fell by 5.81% to $42.0 million in 2023, then spiked by 54.17% to $64.7 million in 2024, then plummeted by 70.32% to $37.0 million in 2025.
  • Its Short-term Investments stands at $37.0 million for Q3 2025, versus $64.0 million for Q2 2025 and $91.9 million for Q1 2025.